AstraZeneca (AZN) has released an update.
AstraZeneca, in partnership with Daiichi Sankyo, has announced that the FDA has accepted their Biologics License Application for datopotamab deruxtecan, a promising treatment for metastatic HR-positive, HER2-negative breast cancer. The application is supported by Phase III trial results, showing significant improvement in progression-free survival. This breakthrough therapy, also being reviewed for non-small cell lung cancer, could offer a more efficacious and better-tolerated alternative to conventional chemotherapy for patients with advanced disease.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
